Skip to main content

Aclaris Therapeutics, Inc 8-K, filed Nov 5, 2026

Aclaris Therapeutics, Inc. (ACRS)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Aclaris Therapeutics, Inc filed this 8-K on November 5, 2026.

Aclaris reported a third-quarter 2026 net loss of $18.5 million, versus $14.6 million a year earlier, with $204.6 million in cash and marketable securities at September 30, 2026. October 2026 sales of stock and pre-funded warrants raised $50.0 million gross, and cash is expected to fund operations through the first half of 2029. Phase 1b trials of ATI-052 showed positive primary results in atopic dermatitis and asthma. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits